Carbohydrate Antigen (CA) 19-9 is a sialylated form of the Lewis blood group antigen. In serum, it exists as a mucin, a high molecular weight (greater than 1 million Daltons) glycoprotein complex with a half-life of approximately 1 day. CA 19-9 is a component of many mucosal cell membranes and their secretory products, but its biological role is unknown. CA 19-9 is produced in the foetal epithelium of the stomach, small and large intestine, liver and pancreas. In the adult, CA 19-9 is synthesised in trace amounts in the pancreas, liver, gallbladder, stomach, colon and lung. Individuals with a Lewis antigen negative blood grouping are unable to synthesise CA 19-9 (approximately 10% of the population).
CA 19-9 is used mainly as a marker of pancreatic carcinoma. Early clinical symptoms of pancreatic carcinoma are minimal and the tumour is usually only diagnosed at a late stage when the prognosis is poor.Measurement of CA 19-9 can aid in diagnosis where pancreatic cancer is suspected, in conjunction with imaging techniques. CA 19-9 measurement can be used for surveillance and monitoring of treatment for pancreatic carcinoma.
Elevated concentrations of CA 19-9 are also found in the following malignancies: gastric cancer, biliary cancers, hepatocellular carcinomas, oesophageal cancers and in miscellaneous non-gastrointestinal cancers.
Serum CA 19-9 concentrations may be elevated in the following benign conditions: hepatitis, hepatic cirrhosis, biliary disease, cystic fibrosis, pancreatitis, diabetes mellitus and rheumatic disease. CA 19-9 is removed from circulation by the liver, so chronic liver disease, particularly with ascites, may cause elevated serum concentrations. Elevated serum CA 19-9 concentrations are not absolute evidence of the presence of malignant disease, and should be used in conjunction with other diagnostic and clinical information
No special patient requirements. Serum assay only , collect blood into yellow/red top vacutainer.
<37 KU/L
Copyright UHB Pathology 2018
Protection of Personal Information – Clinical Laboratory Services comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
University Hospitals Birmingham medical laboratories at Queen Elizabeth Hospital, Heartlands Hospital, Good Hope Hospital and Solihull Hospital are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://qehbpathology.uk/test-database
For further information contact Louise Fallon, Quality Manager, 0121 371 5962